Skip to content

Antidiabetic Potiential of Moringa and Dom Extract

Antidiabetic Potential of Hyphanea Thebaica Fruits and Moringa Olifera Leaves

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05898750
Enrollment
25
Registered
2023-06-12
Start date
2023-04-22
Completion date
2023-06-30
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

The Antidiabetic potential of Hyphaene thebaica fruits and Moringa oleifera leaves will be investigated in diabetic patients (type 2). The patients will be maintained on tea of both drugs for 6 weeks. The fasting blood glucose levels of patients will be checked on a daily basis. Other blood biomarkers will be also reported such as insulin concentration, Lipid profile, liver enzymes, c-peptide and glycated hemoglobin

Interventions

DIETARY_SUPPLEMENTMorDom

oral powder in tea bags contains 4gm twice daily (equal concentration of each drugs)

Sponsors

Deraya University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* diabetic patients type 2

Exclusion criteria

* liver failure * heart failure * renal failure

Design outcomes

Primary

MeasureTime frameDescription
Blood glucose level3 monthsmeasured by fast blood test

Secondary

MeasureTime frameDescription
blood level of lipid profiletwo weeksBlood samples were drawn to measure levels of LDL, HDL, triglycerides, total cholesterol
Liver enzymestwo weeksBlood samples were drawn to measure levels of ALT and AST
C-peptide leveltwo weeksBlood samples were drawn to measure fasting and postprandial levels of c-peptide
Insulin leveltwo weeksBlood samples were drawn to measure fasting and postprandial levels of insulin

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026